Tavotek Biotherapeutics Closes $35M Series B Financing

USA – Tavotek Biotherapeutics, a Lower Gwynedd PA-based biotech company, raised $35M in Series B funding.

The round was led by CS Capital with participation from Fontus Capital. The company intends to use the funds to accelerate: Tavotek Biotherapeutics is advancing medicines for patients suffering from debilitating diseases with significant unmet medical needs. The company has a pipeline of product candidates at various stages of development for cancer, autoimmune conditions, and inflammatory diseases. Its research platforms are built upon three breakthrough technologies: Tavotek has two R&D centers: one in Lower Gwynedd, Pennsylvania and another in Suzhou, China. 19/11/2021